Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
Mené sur 324 patients atteints d'un cancer du pancréas résécable, cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans événement, et la toxicité d'un traitement néoadjuvant combinant nab-paclitaxel et gemcitabine de façon séquentielle suivi d'une chimiothérapie de type FOLFIRINOX modifié
This single-center, randomized phase 3 trial (NCT03750669) evaluated sequential neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX versus upfront surgery in 324 patients with resectable pancreatic cancer. Patients in the neoadjuvant group received nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX before surgery and then four cycles of adjuvant therapy (preferably gemcitabine plus capecitabine), while those in the upfront surgery group underwent immediate resection followed by six cycles of adjuvant therapy. The primary endpoint was event-free survival. Notably, 50% of patients had tumors in the pancreatic body or tail. Median event-free survival was 15.3 months (95% confidence interval [CI], 12.6?19.3) versus 10.9 months (95% CI, 9.1?13.5; hazard ratio [HR], 0.71; 95% CI, 0.54?0.93; p = 0.0136). Median overall survival was 35.4 months versus 27.2 months (HR, 0.73; 95% CI, 0.53?1.00; nominal p = 0.0477). Grade ≥3 adverse events occurred in 47.6% versus 30.7% of patients. This neoadjuvant regimen improves event-free survival with manageable safety.
Cancer Cell , résumé, 2025